Abstract 104P
Background
HLX04, a proposed bevacizumab biosimilar, was developed stepwise with proven analytical and clinical PK similarities. This confirmatory ph3 study (NCT03511963) aimed to compare the safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment in pts with recurrent/metastatic colorectal cancer.
Methods
We conducted this double-blind, multicentre, parallel-controlled, ph3 study (HLX04-mCRC03) in pts (18≤age≤75 years) with histologically/cytologically confirmed unresectable recurrent/metastatic CRC. Eligible subjects were randomised 1:1 to receive either HLX04 or bevacizumab intravenously (7.5 mg/kg Q3W in combination with XELOX or 5 mg/kg Q2W in combination with mFOLFOX6). The primary endpoint was the progression free survival rate at week 36 (PFSR36w) per RECIST v1.1. Secondary endpoints included ORR, 12-month OS rate and DoR. Primary and secondary endpoints were further stratified (by chemotherapy, KRAS/BARF mutation, etc.) for subgroup analyses.
Results
PFSR36w was 46.4% (n=338) in HLX04 and 50.7% (n=337) in bevacizumab per FAS. The group difference was -4.2% (90% CI -10.6%, 2.1%), which fell entirely in the pre-defined equivalence margins (-11%, 15%). No statistically significant difference was observed in primary or secondary endpoints and their subgroup analyses. Similar safety results were demonstrated between the two treatment groups. The most common TEAEs (grade≥3) in both groups were decreased neutrophil count (20.6% vs 20.2%), decreased platelet count (10.3% vs 10.1%) and hypertension (7.4% vs 12.5%). The most common SAEs in both groups were intestinal obstruction (9.0% vs 9.6%) and decreased platelet count (11.2% vs 6.7%). The incidences of death during the treatment was 11 (3.2%) and 9 (2.7%), respectively. The immunogenicity profiles were similar between treatment groups.
Conclusions
HLX04 demonstrated equivalent efficacy and similar safety and immunogenicity profiles with reference bevacizumab as first-line treatment for mCRC, presenting as an alternative option for cancer pts as a biosimilar candidate.
Clinical trial identification
NCT03511963; April 30, 2018.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
L. Zhang, W. Li, K. Chai: Full/Part-time employment: Shanghai Henlius Biotech, Inc. W. Jiang, S. Liu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Shanghai Henlius Biotech, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session